LianBio (LIANY)
LIANY Stock Price Chart
Explore LianBio interactive price chart. Choose custom timeframes to analyze LIANY price movements and trends.
LIANY Company Profile
Discover essential business fundamentals and corporate details for LianBio (LIANY) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
1 Nov 2021
Employees
163.00
Website
https://www.lianbio.comCEO
Adam Leo Stone
Description
LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor and NX-13 for ulcerative colitis and Crohn's disease; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus. It has a partnership with Tarsus Pharmaceuticals, Inc. to develop and commercialize TP-03 for the treatment of Demodex blepharitis; and Nanobiotix S.A. to develop and commercialize NBTXR3, a radioenhancer designed to be injected directly into a malignant tumor prior to standard radiotherapy. The company was incorporated in 2019 and is headquartered in Princeton, New Jersey.
LIANY Financial Timeline
Browse a chronological timeline of LianBio corporate events including earnings releases, dividend announcements, and stock splits.
Dividend declared on 20 Jun 2025
A dividend of $0.43 per share was announced, adjusted to $0.43.
Earnings released on 25 Apr 2025
Earnings released on 28 Mar 2025
Earnings released on 18 Nov 2024
Earnings released on 9 Aug 2024
Earnings released on 2 Apr 2024
Earnings released on 25 Mar 2024
EPS came in at $3.55 surpassing the estimated -$0.19 by +1.97K%.
Dividend declared on 15 Mar 2024
A dividend of $4.75 per share was announced, adjusted to $4.75.
Dividend declared on 26 Feb 2024
A dividend of $4.80 per share was announced, adjusted to $4.80.
Earnings released on 30 Sept 2023
EPS came in at -$0.22 surpassing the estimated -$0.33 by +32.02%.
Earnings released on 30 Jun 2023
EPS came in at -$0.20 surpassing the estimated -$0.29 by +29.97%.
Earnings released on 31 Mar 2023
EPS came in at -$0.22 surpassing the estimated -$0.27 by +17.82%.
Earnings released on 31 Dec 2022
EPS came in at -$0.17 surpassing the estimated -$0.27 by +38.08%.
Earnings released on 29 Sept 2022
EPS came in at -$0.20 surpassing the estimated -$0.39 by +48.90%.
Earnings released on 29 Jun 2022
EPS came in at -$0.39 .
Earnings released on 30 Mar 2022
EPS came in at -$0.26 surpassing the estimated -$0.28 by +5.89%.
Earnings released on 30 Dec 2021
EPS came in at -$0.20 .
Earnings released on 29 Sept 2021
EPS came in at -$0.12 .
Earnings released on 30 Mar 2021
EPS came in at -$3.00 .
LIANY Stock Performance
Access detailed LIANY performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.